new version V2017

renal-cell carcinoma (advanced)
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

angiogenesis inhibitors

bevacizumab
Yang, 2003bevacizumabplacebo Exploratory -
AVOREN, 2007bevacizumab plus interferon alfainterferon alphaSuggesting
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphaSuggesting

immune checkpoint inhibition

atezolizumab
NCT02420821 ongoing atezolizumab + bevacizumab1L Risk of bias - NCT02420821
avelumab
JAVELIN Renal 101 ongoing avelumab + axitinibsunitinib1L, PDL1 positive Risk of bias - NCT02684006
nivolumab
Chekmate 025 (Motzer), 2015nivolumabeverolimus2L Risk of bias SuggestingNCT01668784
CheckMate-214, 2017nivolumab + ipilimumabsunitinib1L Risk of bias ConclusiveNCT02231749
pembrolizumab
KEYNOTE-426 ongoing pembrolizumab + axitinibsunitinib - NCT02853331

multi target TKI

apitolisib
Powles, 2014apitolisibeverolimus -
axitinib
AXIS (Rini), 2011axitinibsorafenibSuggestingNCT00678392
Qin, 2012axitinibsorafenib -
cabozantinib
METEOR, 2015cabozantinibeverolimus after VEGFR-targeted therapy failure Risk of bias SuggestingNCT01865747
CABOSUN, 2017cabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk Exploratory SuggestingNCT01835158
dovitinib
GOLDdovitinibsorafenibNegativeNCT01223027
pazopanib
Sternberg, 2010pazopanibplaceboSuggesting
VEG105192, 2010pazopanibplaceboSuggestingNCT00334282
COMPARZ, 2013pazopanibsunitinibNegativeNCT00720941
sorafenib
Ratain, 2006sorafenibplacebo Exploratory -
TARGET, 2007sorafenibplacebo Low risk of bias SuggestingNCT00073307
Escudier, 2009sorafenibinterferon alpha Exploratory Negative
sunitinib
SWITCHsunitinibsorafenib - NCT00732914
Motzer, 2007sunitinibinterferon alphaSuggestingNCT00083889
tivozanib
TIVO-1, 2013tivozanibsorafenibSuggestingNCT01030783



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons